Biotech Values

[north40000]

I would suggest both GILD and SNY did do as you suggest:
"proactively purchase one" for whatever comes along in their platform for which they might desire review faster than usual.

As exwannabe said elsewhere earlier today:

"So the issue for SNY is to determine what drug not worthy of a priority review will gain that much value by being 4 months early to market. Likely one with competition I would assume."